Healthy scanner sales in internationalmarkets helped Acuson to a third consecutive quarter of positivesales and earnings, despite ongoing uncertainty in the U.S. market.In posting financial results for its third quarter of 1994 (end-October),the Mountain
Healthy scanner sales in internationalmarkets helped Acuson to a third consecutive quarter of positivesales and earnings, despite ongoing uncertainty in the U.S. market.In posting financial results for its third quarter of 1994 (end-October),the Mountain View, CA, vendor reported revenues almost $20 millionhigher than the same period last year.
Acuson's sales for the most recent period were $86.4 million,a 29% increase over the $67.1 million recorded in the same quarterlast year. Earnings were also up, with the company reporting netincome of $3.7 million, a gain of 64% compared to the $2.3 millionrecorded in the third quarter of 1993.
For the nine-month period, Acuson recorded sales of $267 millionover $221 million in the same period last year. Net income forthe year to date is $14.4 million, compared to $572,000 for thefirst nine months of 1993.
Acuson's strong results reflect the company's success in marketsin Europe, Asia and Latin America, according to CFO Stephen Johnson.Acuson started a sales and marketing effort in Latin America thisyear, and that market has shown more demand for premium systemsthan expected, Johnson said.
The U.S. market continues to be flat and shows no signs ofa recovery, although the fourth quarter is traditionally strongfor medical imaging vendors, according to Johnson. Acuson's performancedomestically has been helped by its Acoustic Response Technology(ART) upgrade, which has enjoyed sales of $24 million since itsrelease last year (SCAN 9/14/94).
Acuson also announced last week that it has begun clinicaltesting of its DICOM 3.0 interface for the Aegis ultrasound imagemanagement system. At the University of California at San Francisco,Acuson has linked Aegis to a hospital-wide PACS, while at theVirginia Mason Medical Center in Seattle an Aegis system is sendingimages from the ultrasound department to a Cemax multimodalityclinical workstation.
In other Aegis-related news, John Freund, executive vice presidentand head of the Aegis division, is planning to leave the companyin December. Acuson tapped Freund to lead the division last year(SCAN 12/29/93).
Freund joined Acuson from the investment banking field withthe intention of working for the firm for three years. He endedup staying six, he told SCAN.
Acuson COO Robert Gallagher and vice president of engineeringDonald Burch have been named co-managers of the unit on an interimbasis, although CEO Sam Maslak said Acuson is in no rush to finda replacement for Freund.
"John did just what he and I hoped he would do in termsof helping the division make the transition into a selling andmanufacturing organization," Maslak said.
Seven Takeaways from Meta-Analysis of PSMA Radiotracers for Prostate Cancer Imaging
December 1st 2023In a newly published meta-analysis of 24 studies, researchers noted that the PSMA PET radiotracer 18F PSMA-1007 may provide more benefit than 68Ga Ga-PSMA-11 for primary staging of patients with prostate cancer and detection of local lesion recurrence, but also has drawbacks with higher liver uptake and multiple reports of false positive bone lesions.
Study: Regular Mammography Screening Reduces Breast Cancer Mortality Risk by More than 70 Percent
November 30th 2023Consistent adherence to the five most recent mammography screenings prior to a breast cancer diagnosis reduced breast cancer death risk by 72 percent in comparison to women who did not have the mammography screening, according to new research findings presented at the annual Radiological Society of North America (RSNA) conference.
FDA Clears Magnetic Resonance Spectroscopy Platform for Non-Invasive Assessment of Brain Chemistry
November 29th 2023BrainSpec Core reportedly offers enhanced sensitivity for low-grade gliomas and may facilitate the diagnosis of conditions including Alzheimer’s disease, multiple sclerosis, and epilepsy.